Veracyte Inc. (VCYT) exhibits 70.1% gross margins and 4.6% return on invested capital within Health Care (Medical Specialities), balanced against a 58.7x enterprise multiple and 7.2% implied options volatility.
Sustained 70.1% gross profitability converts into 11.2% operating margin and 4.6% ROIC, outpacing sector cost of capital.
ROIC: 4.6% // GM: 70.1%YoY revenue trajectory of +16.0% paired with 3.02% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +16.0% // FCF YLD: 3.02%Altman Z-Score of 26.00 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 9/9Trading at 63.2x trailing P/E (53.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 63.2x // EV/EBITDA: 58.7xOptions market prices a ±7.2% implied move with a 0.58 put/call ratio around $51.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.58Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend 12.8% net margins.
NET MARGIN: 12.8% // D/E: 0.03x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for VCYT & activate live FRED threshold breach alerts.